AI Advances Poised to Revolutionize RNA Therapeutics Following Flu Vaccine Approval
The field of RNA therapeutics is on the cusp of significant acceleration, driven by recent advancements in artificial intelligence, according to Rhiju Das, PhD, a professor of biochemistry at Stanford Medicine. This follows the U.S. Food and Drug Administration's approval of the first-ever mRNA flu vaccine for adults aged 50 and above in August. Dr. Das notes that while AI-designed small molecule drugs and proteins are already in clinical trials, RNA therapeutics are approximately five years away from similar milestones. His work, including the community science platform Eterna, has shown that AI algorithms can now design RNA molecules as effectively as experienced human participants, leading to the creation of novel, atomically ordered 3D RNA shapes. These AI-generated designs, visualized through cryo-electron microscopy, exhibit intricate interactions previously thought to require billions of years of evolution.